Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics Corp. has unveiled promising preclinical data from its BiSKIT and IL-2 Super Agonist programs, showcasing potential breakthroughs in cancer treatment. Their novel therapies, MDNA113 and MDNA11, have demonstrated significant tumor regression and survival benefits in aggressive cancer models, promising hope for millions affected by tumors worldwide.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
